Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Epilepsia|April 1, 2022
Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trialEllen N Hurley, Carolyn J Ellaway, Alexandra M Johnson, et al.
Asia-Pacific Journal of Clinical Oncology|December 14, 2011
Randomized phase 2 sequencing and pharmacokinetic study of gemcitabine and oxaliplatin in advanced non-small cell lung cancerPaul L Mitchell, Adam Broad, Mark A Rosenthal, et al.
Clinical Epigenetics|January 28, 2023
A phase 1 clinical trial of the repurposable acetyllysine mimetic, n-methyl-2-pyrrolidone (NMP), in relapsed or refractory multiple myelomaJake Shortt, Peter Galettis, Chan Y Cheah, et al.
Biochimie|April 6, 2010
Emerging roles for phospholipase A2 enzymes in cancerKieran F Scott, Mila Sajinovic, Juliane Hein, et al.
Plos One|June 17, 2021
Sodium alginate microencapsulation improves the short-term oral bioavailability of cannabidiol when administered with deoxycholic acidMaimuna Majimbi, Emily Brook, Peter Galettis, et al.
Biosensors|August 25, 2023
Fluoropolymer Functionalization of Organ-on-Chip Platform Increases Detection Sensitivity for CannabinoidsZiqiu Tong, Lars Esser, Peter Galettis, et al.
Cannabis and Cannabinoid Research|August 21, 2023
Daily Cannabidiol Administration for 10 Weeks Modulates Hippocampal and Amygdalar Resting-State Functional Connectivity in Cannabis Users: A Functional Magnetic Resonance Imaging Open-Label Clinical TrialValentina Lorenzetti, Eugene McTavish, Samantha Broyd, et al.
Journal of Inorganic Biochemistry|November 22, 2007
In vitro antitumour and hepatotoxicity profiles of Au(I) and Ag(I) bidentate pyridyl phosphine complexes and relationships to cellular uptakeJohnson J Liu, Peter Galettis, Alistair Farr, et al.
Internal Medicine Journal|July 3, 2019
Model-based analysis on systemic availability of co-administered cannabinoids after controlled vaporised administrationZheng Liu, Peter Galettis, Samantha J Broyd, et al.
Clinical Pharmacokinetics|February 9, 2020
Inability of Current Dosing to Achieve Carboplatin Therapeutic Targets in People with Advanced Non-Small Cell Lung Cancer: Impact of Systemic Inflammation on Carboplatin Exposure and Clinical OutcomesBenjamin D W Harris, Viet Phan, Vidya Perera, et al.
Pageof 6